Maybe, but I rather doubt it. LLY and AZN are badly out of favor with investors—even more so than other Big Pharma. If LLY and AZN were indeed working on FoB’s—or had the intention of doing do—one would think they would have found a way to mention this at some investor presentation.
Market Data 
Markets 
AI
